drugset / Trial / NCT02471274
PK Study of Sotagliflozin in Subjects With Hepatic Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the effect of mild, moderate, or severe hepatic impairment on the pharmacokinetics (PK) of a single dose of 400 mg sotagliflozin (2 x 200-mg tablets) compared with healthy, demographically-matched subjects.
Timeline
- Start
- 2015-06
- Primary completion
- 2015-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sotagliflozin | Small molecule | 400 mg | — |
Indications
No indication recorded.